WO2006051413A8 - Azabenoxazoles for the treatment of cns disorders - Google Patents

Azabenoxazoles for the treatment of cns disorders

Info

Publication number
WO2006051413A8
WO2006051413A8 PCT/IB2005/003427 IB2005003427W WO2006051413A8 WO 2006051413 A8 WO2006051413 A8 WO 2006051413A8 IB 2005003427 W IB2005003427 W IB 2005003427W WO 2006051413 A8 WO2006051413 A8 WO 2006051413A8
Authority
WO
WIPO (PCT)
Prior art keywords
azabenoxazoles
treatment
formula
cns disorders
nicotinic receptor
Prior art date
Application number
PCT/IB2005/003427
Other languages
French (fr)
Other versions
WO2006051413A1 (en
Inventor
Allen Jacob Duplantier
Christopher John O'donnell
Bruce Nelsen Rogers
Lei Zhang
Original Assignee
Pfizer
Allen Jacob Duplantier
Christopher John O'donnell
Bruce Nelsen Rogers
Lei Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Allen Jacob Duplantier, Christopher John O'donnell, Bruce Nelsen Rogers, Lei Zhang filed Critical Pfizer
Publication of WO2006051413A1 publication Critical patent/WO2006051413A1/en
Publication of WO2006051413A8 publication Critical patent/WO2006051413A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to a7 nicotinic receptor agonists of formula I as described herein and to a method for treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal an a7 nicotinic receptor agonist of formula I. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant a7 nicotinic receptor agonist of formula (I).
PCT/IB2005/003427 2004-11-15 2005-11-04 Azabenoxazoles for the treatment of cns disorders WO2006051413A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60896304P 2004-11-15 2004-11-15
US60/608,963 2004-11-15

Publications (2)

Publication Number Publication Date
WO2006051413A1 WO2006051413A1 (en) 2006-05-18
WO2006051413A8 true WO2006051413A8 (en) 2007-06-07

Family

ID=36336253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/003427 WO2006051413A1 (en) 2004-11-15 2005-11-04 Azabenoxazoles for the treatment of cns disorders

Country Status (1)

Country Link
WO (1) WO2006051413A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107188900B (en) * 2017-05-27 2019-09-06 北京师范大学 The ligand compound of alpha 7 nicotinic acetylcholine receptors and its application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2809730B1 (en) * 2000-05-31 2002-07-19 Sanofi Synthelabo 1,4-DIAZABICYCLO [3.2.2] NONANEBENZOXAZOLE, -BENZOTHIAZOLE AND -BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
US20020086871A1 (en) * 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
FR2832714B1 (en) * 2001-11-23 2004-07-16 Sanofi Synthelabo DERIVATIVES OF 4- (OXAZOLOPYRIDIN-2-YL) -1,4-DIAZABICYCLO [3.2.2] NONANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

Also Published As

Publication number Publication date
WO2006051413A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
TW200631956A (en) Azabenzoxazoles for the treatment of CNS disorders
MXPA02001306A (en) Pharmaceutical compositions for the treatment of cns and other discorders.
CA2366268A1 (en) Pharmaceutical compositions for cns and other disorders
UA86621C2 (en) Glucagon receptor antagonists, preparation and therapeutic uses
HK1179961A1 (en) Morphinan compounds
SI1957484T1 (en) Glucagon receptor antagonists, preparation and therapeutic uses
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
PL1735278T3 (en) Histamine h3 receptor agents, preparation and therapeutic uses
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007114855A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
GB9917822D0 (en) Nmda antagonist
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
MXPA01008993A (en) Combination treatment for depression and anxiety.
EP1213031A3 (en) Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
TW200833337A (en) Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline
TW200628476A (en) Azabenzoxazoles for the treatment of CNS disorders
WO2006051413A8 (en) Azabenoxazoles for the treatment of cns disorders
HUP0401967A2 (en) Use of nicotinic acetylcholine receptor agonists for preparation of pharmaceutical compositions available in the treatment of restless legs syndrome
WO2005062894A3 (en) Co-administration of dopamine-receptor binding compounds
WO2005097757A3 (en) Nucleoside derivatives and therapeutic use thereof
EP1633695A4 (en) Smooth muscle spasmolytic agents
EP1099446A3 (en) Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent
EP1064948A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
EP1260221A3 (en) Combination treatment for depression and anxiety

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05812677

Country of ref document: EP

Kind code of ref document: A1